Get the Stockscreener App
3.20
0.95%
0.03
Immutep Limited Adr stock is traded at $3.20, with a volume of 7,899.
It is up +0.95% in the last 24 hours and down -39.87% over the past month.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
See More
Previous Close:
$3.17
Open:
$3.21
24h Volume:
7,899
Relative Volume:
0.48
Market Cap:
$23.58M
Revenue:
$2.67M
Net Income/Loss:
$-54.17M
P/E Ratio:
-8.651
EPS:
-0.3699
Net Cash Flow:
$-39.34M
1W Performance:
+0.00%
1M Performance:
-39.87%
6M Performance:
-71.97%
1Y Performance:
-92.04%
1-Day Range:
$3.10
$3.23
1-Week Range:
$3.0727
$3.4195
52-Week Range:
$3.06
$70.60
Immutep Limited Adr Stock (IMMP) Company Profile
Compare IMMP vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
3.20 | 23.58M | 2.67M | -54.17M | -39.34M | -0.3699 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Downgrade | Citizens | Mkt Outperform → Mkt Perform |
| Mar-13-26 | Downgrade | Maxim Group | Buy → Hold |
| Mar-13-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-17-26 | Initiated | Citizens | Mkt Outperform |
| May-17-24 | Initiated | CapitalOne | Overweight |
| Aug-03-23 | Initiated | Robert W. Baird | Outperform |
| Aug-03-21 | Initiated | Ladenburg Thalmann | Buy |
| Jul-16-21 | Resumed | Maxim Group | Buy |
| Sep-28-18 | Initiated | B. Riley FBR | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
View All
Immutep Limited Adr Stock (IMMP) Latest News
After 10 business days at $1 or more, Immutep (Nasdaq: IMMP) gets Nasdaq’s bid-price decision. - Stock Titan
Nasdaq closed Immutep's listing case after 10 business days meeting the $1 bid minimum. - Stock Titan
Immutep Restores Nasdaq Bid Price Compliance with ADS Ratio Change - The Globe and Mail
Immutep Restores Nasdaq Bid Price Compliance with ADS Ratio Change - TipRanks
Immutep Regains Nasdaq Minimum Bid Price Compliance After ADS Ratio Change Effective 28 September 2026 - Kalkine
Immutep Achieves Nasdaq Minimum Bid Price Compliance Following ADS Ratio Adjustment Effective September 28, 2026 - Kalkine Media
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
Immutep (NASDAQ: IMMP) Announces ADS Ratio Adjustment Effective September 28 to Meet Nasdaq Price Criteria - Kalkine Media
Immutep Resets ADS Ratio to Bolster Nasdaq Listing Compliance - TipRanks
Immutep (IMMP) plans 1-for-20 ADS reverse split to address Nasdaq bid-price deficiency - Stock Titan
Immutep Plans Reverse Split of Nasdaq-Listed American Depositary Shares - marketscreener.com
Change to American Depositary Share Ratio - GlobeNewswire
A Nasdaq $1 price rule is behind Immutep’s planned 20-for-1 share swap - Stock Titan
Immutep Adjusts ADS Ratio to Safeguard Nasdaq Listing - TipRanks
Immutep (IMMP) retools lead cancer drug after trial halt, with next studies years away - Stock Titan
Immutep (IMMP) Slips to $0.36 as Biotech Stock Tests Key Support ZoneValue Area High - careplusvn.com
Immutep (IMMP) Slips to $0.36 as Biotech Stock Tests Key Support ZoneAAII Neutral - siam.in
Immutep (IMMP) Slips to $0.36 as Biotech Stock Tests Key Support ZoneMomentum Factor - dars.gov.et
Immutep (IMMP) Slips to $0.36 as Biotech Stock Tests Key Support ZoneRatio Spread Trade - dars.gov.et
Immutep (NASDAQ: IMMP) halts Phase III lung cancer trial and returns cash to Dr Reddy’s - Stock Titan
IMMP Q2 2026 Earnings: Loss per ADS of $0.03 Misses Estimates as Clinical Pipeline Investment ContinuesCapex Guidance - careplusvn.com
IMMP Q2 2026 Earnings: Loss per ADS of $0.03 Misses Estimates as Clinical Pipeline Investment ContinuesEPS Surprise History - dars.gov.et
IMMP Q2 2026 Earnings: Loss per ADS of $0.03 Misses Estimates as Clinical Pipeline Investment Continues - dars.gov.et
IMMP Q2 2026 Earnings: Loss per ADS of $0.03 Misses Estimates as Clinical Pipeline Investment ContinuesLow Growth Earnings - dars.gov.et
IMMP Q2 2026 Earnings: Loss per ADS of $0.03 Misses Estimates as Clinical Pipeline Investment ContinuesEPS Guidance Update - dars.gov.et
Immutep (IMMP) Technicals: Ends Little Changed at $0.39 for the Current Session; Levels: the $0.37 to $0.41 Range Remains in Focus in the Latest ReadingSchiff Line - siam.in
Immutep (IMMP) Technicals: Ends Little Changed at $0.39 for the Current Session; Levels: the $0.37 to $0.41 Range Remains in Focus in the Latest ReadingMoney Flow Index - dars.gov.et
Immutep (IMMP) Technicals: Ends Little Changed at $0.39 for the Current Session; Levels: the $0.37 to $0.41 Range Remains in Focus in the Latest ReadingTrend Continuation Trade - dars.gov.et
Immutep (IMMP) Technicals: Ends Little Changed at $0.39 for the Current Session; Levels: the $0.37 to $0.41 Range Remains in Focus in the Latest ReadingHigh Dividend Factor - dars.gov.et
Immutep (IMMP) Technicals: Ends Little Changed at $0.39 for the Current Session; Levels: the $0.37 to $0.41 Range Remains in Focus in the Latest ReadingReversal Trade - www.dars.gov.et
Immutep (IMMP) Stock: Ends Down by 0.84% at $0.39 in Latest Trading; Immediate View: the Session Ends Within the Reported Technical Boundaries in the Available RecordLeading Diagonal - dars.gov.et
Immutep (IMMP) Trading: Finishes 1.01% Lower at $0.39 in Latest Trading; Next Session: the Current Price Sits Inside the Supplied Technical Range at the CloseIchimoku TK Cross - careplusvn.com
Immutep (IMMP) Trading: Finishes 1.01% Lower at $0.39 in Latest Trading; Next Session: the Current Price Sits Inside the Supplied Technical Range at the CloseRisk Reversal - dars.gov.et
Immutep (IMMP) Results Review: EPS Falls Short of Its Estimate at the Close; Investor Response: Shares Move Lower 1.01% in the Latest SessionGuidance Revision Trend - dars.gov.et
Immutep (IMMP) Trading: Finishes 1.01% Lower at $0.39 in Latest Trading; Next Session: the Current Price Sits Inside the Supplied Technical Range at the CloseOvervalued Signals - dars.gov.et
Immutep (IMMP) Results Review: EPS Falls Short of Its Estimate at the Close; Investor Response: Shares Move Lower 1.01% in the Latest SessionEarnings Growth Analysis - dars.gov.et
Immutep (IMMP) Results Review: EPS Falls Short of Its Estimate at the Close; Investor Response: Shares Move Lower 1.01% in the Latest SessionQuarterly Earnings - dars.gov.et
Immutep (IMMP) Holds Steady at $0.38 as Shares Test Key Support ZoneMcClellan Summation - careplusvn.com
IMMP Q2 2026 Earnings: Pre-Revenue Loss Misses by 9.89%, Yet Shares Gain 2.85%Quarterly Earnings - careplusvn.com
IMMP Q2 2026 Earnings: Wider-Than-Expected Loss, Yet ADS Advances 2.85%Balance Sheet Strength - dars.gov.et
Immutep Ltd Sponsored ADR Revenue Breakdown – FWB:YP1A - TradingView
Immutep Ltd Sponsored ADR Revenue Breakdown – MUN:YP1A - TradingView
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Immutep (IMMP) Retreats After Recent Gains, Testing Key Support at $0.39Low Beta Factor - careplusvn.com
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Immutep (ASX:IMM) Shares Surge Nearly 14% as Healthcare Momentum Grabs the ASX Spotlight - Kalkine
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
Immutep Limited Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsIMMP - Finansavisen
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming DeadlinesIMMP - Finansavisen
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Graphic Packaging Holding Company (GPK), Immutep Limited (IMMP), and Phreesia, Inc. (PHR) Announced by Holzer & Holzer, LLC - GlobeNewswire Inc.
Immutep Limited Adr Stock (IMMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.09%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):